4 May 2017 - Fast track designation for SB-FIX in vivo genome editing treatment for haemophilia B.

Sangamo Therapeutics announced today that the company has received notice from the U.S. FDA of special regulatory designations for three of the company's clinical programs.

The SB-FIX program has already received orphan drug designation from the FDA. FDA has cleared an IND for this program, and a Phase 1/2 clinical trial evaluating SB-FIX in adults with haemophilia B is open and screening subjects for enrolment.

Read Sangamo Therapeutics press release